Your browser doesn't support javascript.
loading
Secondary pneumothorax as a potential marker of apatinib efficacy in osteosarcoma: a multicenter analysis.
Tian, Zhichao; Liu, Huimin; Zhao, Yao; Wang, Xiaofeng; Ren, Hongyan; Zhang, Fan; Li, Po; Zhang, Peng; Wang, Jiaqiang; Yao, Weitao.
Afiliação
  • Tian Z; Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital.
  • Liu H; Department of Medical Oncology, the Affiliated People's Hospital of Zhengzhou University.
  • Zhao Y; Department of Orthopedics.
  • Wang X; Department of Medical Oncology, the First Affiliated Hospital of Zhengzhou University.
  • Ren H; Pneumology Department, the Affiliated People's Hospital of Zhengzhou University, Zhengzhou 450003, Henan Province, China.
  • Zhang F; Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital.
  • Li P; Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital.
  • Zhang P; Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital.
  • Wang J; Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital.
  • Yao W; Department of Orthopedics, the Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital.
Anticancer Drugs ; 2020 Nov 12.
Artigo em Inglês | MEDLINE | ID: mdl-33105152
ABSTRACT
This study was performed to investigate pneumothorax characteristics and association with clinical outcomes in patients with osteosarcoma treated with apatinib. We retrospectively reviewed the medical records of osteosarcoma patients treated with apatinib between January 2016 and April 2020 at three institutions. We evaluated the prevalence, healing time, recurrence, severity, clinical management, and prognosis of pneumothorax in these patients. A total of 54 osteosarcoma patients who received apatinib treatment were enrolled in this study. Among them, 14 patients had pneumothorax. There were significant differences between the patients with and without pneumothorax with regard to the cavitating rate of lung metastases (92.86 vs. 32.50%, respectively, P < 0.001), objective response rate (42.86 vs. 10.00%, P = 0.013), disease control rate (85.71 vs. 42.50%, P = 0.006), 4-month progression-free survival (PFS) rate (57.10 vs. 20.00%, P < 0.001), and median PFS (5.65 vs. 2.90 months, P = 0.011). Compared with pneumothorax patients treated with chest tube drainage only [non-staphylococcal enterotoxin C (SEC) group], those treated with chest tube drainage and SEC thoracic perfusion in parallel (SEC group) had a shorter pneumothorax healing time (12.00 ± 4.50 days vs. 24.00 ± 14.63 days for SEC group and non-SEC group, respectively, P = 0.103), a lower recurrence rate of pneumothorax (25.00% vs. 66.67%, P = 0.277), and a longer median PFS (5.9 months vs. 4.75 months, P = 0.964). however, these numerical differences for the SEC/non-SEC data did not reach statistical significance. Pneumothorax and cavitation in lung metastases may be effective prognostic markers for patients with osteosarcoma treated with apatinib. SEC may be effective for treatment of such pneumothorax patients, warranting further study.
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Estudo prognóstico / Fatores de risco Idioma: Inglês Assunto da revista: Antineoplasicos Ano de publicação: 2020 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Estudo prognóstico / Fatores de risco Idioma: Inglês Assunto da revista: Antineoplasicos Ano de publicação: 2020 Tipo de documento: Artigo